Профилактика и управление предиабетическими нарушениями углеводного обмена у больныхс метаболическим синдромом

1. Аметов А.С., Дедов И.И. Эндокринология - вчера, сегодня, завтра. // Русский медицинский журнал. 2005. Т. 13, № 6 (230). С. 288-294.

2. Клебанова Е.М., Креминская В.М., Балаболкин М.И. Розиглитазон и другие тиозолидиндионы в лечении сахарного диабета типа 2 // Фарматека. 2005. № 3(99). С. 14-19.

3. Am. College of Physicians. The effect of diet and exercise or Metformin on the metabolic syndrome. AHJ. 2005;142 (8):1-42.

4. Barclay L. Medscape Medical News. New definition of the metabolic syndrome: a newsmaker interview with Sir George Alberti, MA, DPhil, BMBCh. Available at: http:. www.medscape.com/viewarticle/504382 Accessed July 8, 2005.

5. Califf R.M. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J. 2003;5:13-8.

6. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomized trial. Lancet. 2002;359:2072-2077.

7. Chiasson J.L., Josse R.G., Gomis R. et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003 Jul 23;290 (4):486-94.

8. Cleary P., Orchard T., Zinman B. et al. Coronary calcification in the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort for the DCCT/EDIC study group. Program and abstracts of the American Diabetes Association 63rd Annual Scientific Sessions; June 13-17, 2003; New Orleans, Louisiana.

9. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial http://lancet.com (published online September 15, 2006).

10. FDA panel gives thumbs down to Rimonabant www.cardiologytoday.com/200707/fda.asp

11. Gerstein H.C., Yusuf S., Holman R., Bosh J., Pogue J. Rationale,design and recruitment caracteristics of large,simple international trial of diabetes prevention: the DREAM trial Diabetologia 2004;47:1519-1527

12. Hamman R. Late-breaking trials. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10-14, 2005; San Diego, California. Presented June 12, 2005.

13. Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.

14. James W.P.T., Finer N., Hilsted J., Kopelman P., et al. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. Lancet. 2000;356:2119-2125.

15. Khaw K.T., Wareham N., Bingham S. et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413-20.

16. Lindstrm J., Louheranta A., Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabet Care. 2003;26:3230-6.

17. Nestro R.W. et al.Thiazolidinedione use,fluid,retention,and congestive heart failure:the consensus statement from the AHA and ADA. Circulation. 2003;108:2941-2948.

18. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10-14, 2005; San Diego, California. Presented June 12, 2005.

19. Program and abstracts of the 67th Scientific Sessions of the American Diabetes Association; June 22-23, 2007; Chicago, USA. Presented June 22, 2007.

20. Scheen A. Late breaking clinical trials. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10-14, 2005; San Diego, California.

21. Semencovich C.F. TZDs and diabetes: testing the waters. Nat Med. 2005;11:822-824.

22. Targerson J.S. XENDOS - a Unique Advantage Abstract Book Satellite Symp, May 2003, Helsinki.

23. The Diabetes Prevention Program Research Group (2003) Prevention of type 2 diabetes with troglitazon in the Diabetes Prevention Program Diabetes. 52:A58.

24. The 19th World Diabetes Congress, organized by the IDF, Cape Town, South Africa, 3-7 December, 2006. www.idf2006.org

25. Tuomilehto J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Medicine. 2001;344;1343-1350.

26. Kendall D.M., Kim D., Poon T. et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10-14, 200.